Vicore Pharma is

A drug-development company at the international cutting edge of research on the AT2 receptor. The company's portfolio contains small molecules with potential indications including anti-inflammation, nerve generation and cardiovascular disease. Our vision is to lead the development of new molecules with agonistic action to the AT2 receptor into successful clinical drug entities. 


Vicore Pharma is granted orphan drug designation for C21 for the treatment of IPF2016-08-01Vicore Pharma beviljas särläkemedelsstatus för C21 för behandling av IPF2016-08-01Show more news

The AT2 receptor

The AT2 receptor is expressed and activated in the fetus where it supports organ development and differention, and in damaged adult tissue where it restitutes morphology and function, restores heart function after myocardial infarction, reduces inflammation, regenerates neural tissue - to mention but a few of the beneficial effects.


Bio Japan2016-10-12 - 2016-10-14Pacifico, Yokohama, Japan Delårsrapport Jan-Okt, 20162016-10-13 Show more events